New Perspectives, Challenges and Innovations in Modern Personalized Gynaecologic Oncology

A special issue of Journal of Personalized Medicine (ISSN 2075-4426). This special issue belongs to the section "Clinical Medicine, Cell, and Organism Physiology".

Deadline for manuscript submissions: 10 September 2024 | Viewed by 1924

Special Issue Editor


E-Mail
Guest Editor
2nd Department of Obstetrics and Gynaecology, Aristotle University of Thessaloniki, 541 24 Thessaloniki, Greece
Interests: gynecologic oncology; advance laparoscopic surgery; clinical research
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Gynecologic oncology is a subspecialty of obstetrics and gynecology that specifically deals with the diagnosis and treatment of all forms of cancers affecting the female reproductive system, namely endometrial cancer, ovarian cancer, cervical cancer, vulvar cancer, and breast cancer. Modern diagnostics and the therapeutic management of gynecologic cancers often involve a multidisciplinary approach, including surgery, chemotherapy, and radiation therapy.

Modern practice in gynecologic oncology is characterized by continuous innovation in all aspects of diagnosis and treatment. Surgical approaches have been characterized by the inclusion of innovative techniques, such as sentinel node biopsy, laparoscopic treatment, hyperthermic intraperitoneal chemotherapy (HIPEC), the advancing radicality of debulking surgery, and late interest in the potential value of robotic surgery. Furthermore, chemotherapy has been characterized by the innovation of new agents, such as PARP inhibitors, as well as continuous alterations in various protocols in order to optimize treatment and minimize side effects. Radiotherapy has also managed to properly tailor fields of variation using imaging modalities so that it included definitive therapeutic management, such as in advanced-stage cervical cancer.

In this field, continuous updates on any modern innovation, perspective, and challenge are of paramount clinical importance in gynecologic oncology. This Special Issue is open to both original and review articles on any of the aforementioned domains that sit in the center of interest of any kind of innovation and challenge in modern gynecologic oncology. Surgery, chemotherapy, radiation, palliative therapy, individualizing cancer care, and ethics are some, but not all, of potential areas of interest. We welcome your high-quality submissions centered around innovation and modern challenges in an effort to optimize the treatment and prognosis of gynecological oncology patients.

Dr. Stamatios N. Petousis
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Personalized Medicine is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • gynecologic oncology
  • surgical oncology
  • medical oncology
  • radiation oncology
  • diagnosis
  • ethics
  • palliative treatment

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Review

18 pages, 700 KiB  
Review
Prophylactic Antibiotics before Gynecologic Surgery: A Comprehensive Review of Guidelines
by Stamatios Petousis, Panagiota Angelou, Aristarchos Almperis, Antonio Simone Laganà, Gerasimos Titilas, Chrysoula Margioula-Siarkou and Konstantinos Dinas
J. Pers. Med. 2024, 14(3), 327; https://doi.org/10.3390/jpm14030327 - 21 Mar 2024
Viewed by 1798
Abstract
Surgical site infections (SSIs) refer to infections in the incision, organ, or postoperative space. As common healthcare-associated infections, SSIs correlate with prolonged hospital stay, additional procedures, ICU stay, and higher mortality rates. Around 8–10% of gynecologic surgery patients may experience infectious complications, influenced [...] Read more.
Surgical site infections (SSIs) refer to infections in the incision, organ, or postoperative space. As common healthcare-associated infections, SSIs correlate with prolonged hospital stay, additional procedures, ICU stay, and higher mortality rates. Around 8–10% of gynecologic surgery patients may experience infectious complications, influenced by microbial contamination, surgical nature, and patient factors. The goal of this narrative review is to compare and merge recommendations from globally published guidelines concerning the utilization of antibiotics in the perioperative phase. A comparative descriptive/narrative review of the guidelines issued by the American College of Obstetrics and Gynecology (ACOG), Society of Obstetricians and Gynecologists of Canada (SOGC), Royal College of Obstetricians and Gynecologists (RCOG), National Institute for Health and Care Excellence (NICE), Royal Australian and New Zealand College of Obstetricians and Gynecologists (RANZCOG), European Society of Gynecologic Oncology (ESGO), Société Française d’ Anésthesie et de Réanimation (SFAR), Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC), and Hellenic Society of Obstetrics and Gynecology (HSOG) was conducted. For hysterectomy, first/second-generation cephalosporins are suggested, with metronidazole as an option. Laparoscopy without entering the bowel or vagina typically does not require prophylaxis. Uterine evacuation and hysteroscopy may involve doxycycline or azithromycin based on risk factors, whereas, for vulvectomy, cefazolin is recommended. Urogynecology procedures may include cefazolin with metronidazole. In cases of penicillin allergy, cephalosporins are suggested, and, for obese patients, adjusted doses are advised. Additional doses may be needed for prolonged procedures or excessive blood loss. Timing recommendations are 15–60 min before incision, adjusting for specific antibiotics. Clear indications exist for certain surgeries like hysterectomy, termination of pregnancy, and urogynecologic procedures. Conversely, procedures such as intrauterine device insertion, hysteroscopy, and laparoscopy typically do not necessitate antibiotic prophylaxis. For several other procedures, the evidence is inconclusive, while considering dose, timing, and indications can mitigate infectious complications and provide benefits for the healthcare system. Full article
Show Figures

Figure 1

Back to TopTop